Jupiter Endovascular is creating a new class of endovascular procedures that use its proprietary Transforming Fixation (TFX) technology, which can flexibly navigate vasculature and then pressurize to stabilize at the treatment site. The technology is integrated into the company’s Vertex catheter system, which just received FDA 510(k) clearance. Initial clinical focus is pulmonary embolism: the SPIRARE I first-in-human study treated 10 intermediate-risk PE patients in Europe and results will be presented at TCT 2025, while the pivotal SPIRARE II trial is enrolling up to 145 patients across up to 25 U.S. and European sites. Beyond pulmonary embolism, Jupiter plans to extend TFX to additional high-need cardiovascular applications. Proceeds from its latest financing will fund completion of SPIRARE II, commercialization preparations, and pipeline expansion. The oversubscribed Series B, which exceeded its $40 million target, positions the company to advance toward market launch; no revenue or user figures have been disclosed.

Total raised

$61M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2025